[go: up one dir, main page]

MX2017005848A - Composicion farmaceutica que comprende un betabloqueante y un inhibidor de la enzima de conversion. - Google Patents

Composicion farmaceutica que comprende un betabloqueante y un inhibidor de la enzima de conversion.

Info

Publication number
MX2017005848A
MX2017005848A MX2017005848A MX2017005848A MX2017005848A MX 2017005848 A MX2017005848 A MX 2017005848A MX 2017005848 A MX2017005848 A MX 2017005848A MX 2017005848 A MX2017005848 A MX 2017005848A MX 2017005848 A MX2017005848 A MX 2017005848A
Authority
MX
Mexico
Prior art keywords
bisoprolol
pharmaceutical composition
perindoril
composition
perindropyl
Prior art date
Application number
MX2017005848A
Other languages
English (en)
Other versions
MX372717B (es
Inventor
Fonknechten Gilles
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52345359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017005848(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2017005848A publication Critical patent/MX2017005848A/es
Publication of MX372717B publication Critical patent/MX372717B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica fija que comprende un betabloqueante, bisoprolol, y un inhibidor de la enzima de conversión de la angiotensina, perindropil y, utilización de dicha composición para el tratamiento y la prevención de enfermedades cardiovasculares y más particularmente hipertensión arterial, enfermedad coronaria estable o insuficiencia cardiaca crónica.
MX2017005848A 2014-11-05 2015-11-04 Composición farmacéutica que comprende un betabloqueador y un inhibidor de la enzima convertidora de angiotensina. MX372717B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1460654A FR3027803B1 (fr) 2014-11-05 2014-11-05 Composition pharmaceutique comprenant un betabloquant et un inhibiteur de l'enzyme de conversion
PCT/FR2015/052975 WO2016071631A1 (fr) 2014-11-05 2015-11-04 Composition pharmaceutique comprenant le bisoprolol et le périndopril

Publications (2)

Publication Number Publication Date
MX2017005848A true MX2017005848A (es) 2017-06-27
MX372717B MX372717B (es) 2020-05-26

Family

ID=52345359

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005848A MX372717B (es) 2014-11-05 2015-11-04 Composición farmacéutica que comprende un betabloqueador y un inhibidor de la enzima convertidora de angiotensina.

Country Status (24)

Country Link
EP (1) EP3215130B1 (es)
CY (1) CY1123322T1 (es)
DK (1) DK3215130T3 (es)
EA (1) EA032808B1 (es)
ES (1) ES2811904T3 (es)
FR (1) FR3027803B1 (es)
GE (1) GEP20196989B (es)
HR (1) HRP20201518T1 (es)
HU (1) HUE051947T2 (es)
LT (1) LT3215130T (es)
MA (1) MA40915B1 (es)
MX (1) MX372717B (es)
MY (1) MY187357A (es)
PH (1) PH12017500786B1 (es)
PL (1) PL3215130T3 (es)
PT (1) PT3215130T (es)
RS (1) RS60657B1 (es)
RU (1) RU2702362C2 (es)
SG (2) SG10201903656RA (es)
SI (1) SI3215130T1 (es)
TN (1) TN2017000170A1 (es)
UA (1) UA122131C2 (es)
WO (1) WO2016071631A1 (es)
ZA (1) ZA201703078B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4419510T3 (da) 2021-10-20 2025-11-17 Servier Lab Nye trimetazidinsalte
AR132479A1 (es) 2023-04-20 2025-07-02 Servier Lab Nuevas fases sólidas de trimetazidina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2483099A1 (en) 2002-05-03 2003-11-13 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
WO2007010501A2 (en) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
PL2857014T3 (pl) 2010-05-06 2016-12-30 Kompozycja farmaceutyczna zawierająca aspirynę i bisoprolol

Also Published As

Publication number Publication date
MY187357A (en) 2021-09-22
EP3215130B1 (fr) 2020-07-08
HUE051947T2 (hu) 2021-03-29
TN2017000170A1 (fr) 2018-10-19
SI3215130T1 (sl) 2020-11-30
RU2017115341A (ru) 2018-11-05
FR3027803B1 (fr) 2018-02-09
PH12017500786B1 (en) 2023-10-11
MA40915B1 (fr) 2020-08-31
RS60657B1 (sr) 2020-09-30
PT3215130T (pt) 2020-08-26
PL3215130T3 (pl) 2020-11-16
EA032808B1 (ru) 2019-07-31
SG10201903656RA (en) 2019-05-30
FR3027803A1 (fr) 2016-05-06
EP3215130A1 (fr) 2017-09-13
SG11201703550SA (en) 2017-06-29
ZA201703078B (en) 2020-11-25
WO2016071631A1 (fr) 2016-05-12
HRP20201518T1 (hr) 2020-12-11
UA122131C2 (uk) 2020-09-25
DK3215130T3 (da) 2020-09-21
GEP20196989B (en) 2019-07-10
EA201790772A1 (ru) 2017-09-29
ES2811904T3 (es) 2021-03-15
LT3215130T (lt) 2020-08-25
RU2017115341A3 (es) 2019-05-21
MX372717B (es) 2020-05-26
RU2702362C2 (ru) 2019-10-08
CY1123322T1 (el) 2021-12-31
PH12017500786A1 (en) 2017-10-02

Similar Documents

Publication Publication Date Title
BR112015031864A2 (pt) compostos de pirimidinadiona contra as condições cardíacas
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
CL2016000405A1 (es) Uso de bardoxolón metilo o análogos del mismo para el tratamiento y/o prevención de la disfunción endotelial.
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
ECSP19077969A (es) Compuesto heterociclico
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2020011100A (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar.
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
CL2011000165A1 (es) Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento y/o la prevencion del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CL2014000393A1 (es) Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.
WO2015179823A3 (en) Lung localized inhibitors of alpha(v)beta 6
CO2017002813A2 (es) Derivados estabilizados de adrenomedulina y uso de los mismos
MX2017014830A (es) Metodo para tratar las enfermedades roya del cafe, mancha negra de los citricos, sarna de los citricos y sigatoka negra de la banana.
CL2018001157A1 (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
MX2017005848A (es) Composicion farmaceutica que comprende un betabloqueante y un inhibidor de la enzima de conversion.
CL2020001578A1 (es) Compuesto mejorado para tratamiento de insuficiencia cardiaca.
MX2021008102A (es) Composicion para el diagnostico o tratamiento de condiciones asociadas con actividad aumentada del factor de iniciacion de traduccion eucariotica 4e (eif4e) que comprende un inhibidor de eif4e.
CL2007001794A1 (es) Compuestos derivados de 2-imidazolidinona, inhibidores del canal de potasio kv1.5; composicion farmaceutica que los comprende; y su uso para tratar o prevenir arritmias cardiacas. tromboembolia,apoplejia,insuficiencia cardiaca.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
NI202000017A (es) Composición farmacéutica para la prevención o el tratamiento de enfermedades cardiovasculares acompañadas por diabetes, que incluye amlodipino, losartán y rosuvastatina, y preparación compuesta que incluye los mismos
MX389586B (es) Composicion farmaceutica que comprende un betabloqueante, un inhibidor de la enzima de conversion y un antihipertensivo o un aine
CL2015003780A1 (es) Compuestos derivados pirimido-isoquinolin-quinonas, sus sales, isomeros, tautomeros farmacéuticas aceptables; composiciones farmáceuticas; procedimiento de preparación; y su uso en el tratamiento de enfermedades bacterianas y bacterianas multirresistentes.
CL2019002315A1 (es) Nuevo uso médico del compuesto iii.

Legal Events

Date Code Title Description
FG Grant or registration